MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2023 Financial Results
TORONTO, March 22, 2024 /PRNewswire/ – MediPharm Labs Corp. (TSX:LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it will release its full year and fourth quarter financial results for the period ended December 31, 2023, before markets open on Wednesday, March 27, 2024.
Related news for (MEDIF)
- MediPharm Labs Positioned for Unique Opportunities on Possible Rescheduling of Cannabis in the United States
- Apollo Capital Releases Investor Presentation Highlighting Plan to Make MediPharm Labs the World’s Leading International Medical Cannabis Company
- MediPharm Labs’ Founder-CEO Pat McCutcheon Throws his Support behind Apollo Capital as Dissident
- MediPharm Labs Closes $4.5 Million Sale of Hope, BC Facility and Announces Plans to Expand EU GMP Cultivation Capacity at Napanee Facility
- MediPharm Labs Refuses to Answer Direct Questions Regarding Credible Securities Fraud Allegations Says Apollo Capital